{
    "clinical_study": {
        "@rank": "21871", 
        "arm_group": {
            "arm_group_label": "single arm paclitaxel and cisplatin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Esophageal cancer is a highly aggressive malignancy with a poor overall outcome.\n\n        -  Five year survival rate after radical esophagectomy is modest at about 40%.The patients\n           with regional lymph node metastases have worse outcome than those without lymph node\n           metastases.\n\n        -  No standard postoperative adjuvant chemotherapy has ever been established."
        }, 
        "brief_title": "Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Esophageal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Squamous Cell", 
                "Esophageal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ability to give informed consent\n\n          -  histological proof of thoracic esophageal squamous cell carcinoma with negative\n             proximal and distal margins\n\n          -  node-positive and pathologic stage M0 .\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Patients were enrolled 4 to 10 weeks after surgery.\n\n          -  Adequate organ function was required in 2 weeks of registration and was defined as:\n             serum creatinine within normal institutional limit, and creatinine clearance (CrCl)\n             \u226560ml/minute. Aspartate aminotransferase and bilirubin\uff1c2 times of upper normal\n             institutional limits.\n\n        Exclusion Criteria:\n\n          -  prior chemotherapy or concurrent radiation therapy before esophagectomy\n\n          -  R1 or R2 resection\n\n          -  clinically significant hearing loss or symptomatic peripheral neuropathy during\n             initial examination"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133612", 
            "org_study_id": "CH-GI-026"
        }, 
        "intervention": {
            "arm_group_label": "single arm paclitaxel and cisplatin", 
            "description": "The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.", 
            "intervention_name": "paclitaxel; cisplatin", 
            "intervention_type": "Drug", 
            "other_name": "Paclitaxel Injection, Beijing Union Pharmaceutical Factory"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "esophageal cancer", 
            "adjuvant chemotherapy", 
            "esophageal surgery", 
            "paclitaxel", 
            "cisplatin"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100021"
                }, 
                "name": "Xiao Lv"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Patients With Advanced Esophageal Cancer", 
        "other_outcome": {
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "5 year"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Jing Huang, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "3 year overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "5 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133612"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Jing Huang", 
            "investigator_title": "M.D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "3 year disease-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "5 year"
        }, 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2007", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}